and nonfatal asthma exacerbations. Purpose: To assess the risk for severe, life-threatening, or fatal asthma exacerbations associated with long-acting -agonists. Data Sources: English- and non–English-language searches of MEDLINE, EMBASE, and Cochrane databases; the U.S. Food and Drug Administration Web site; and references of selected review
Epidemiological evidence has suggested a link between beta2-agonists and increased asthma mortality....
AbstractThe development of inhaled agonists selective for β2-adrenoceptors and high potency corticos...
SummaryWe investigated the relationship between asthma mortality and long-acting beta2-agonists (LAB...
Long-acting -agonists are a pillar of therapy for many patients with asthma because they are the pre...
Background: Recent analyses have suggested an increased risk for serious asthma-related adverse even...
Several studies suggested an association between the regular use of β2-agonists and asthma deaths. ...
In a recent meta-analysis, Salpeter and colleagues documented a significant increase in life-threate...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
Background: It is unclear whether long-acting β-agonists with concomitant inhaled corticosteroids...
Large surveillance studies or phase IV clinical studies of long-acting β-agonists (LABA) compared wi...
Objective To determine the comparative effectiveness and safety of current maintenance strategies in...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
In patients with asthma, do long-acting β-agonists (LABAs) increase risk for asthma-related intubati...
International audienceBACKGROUND: Although several systematic reviews investigated the safety of lon...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
Epidemiological evidence has suggested a link between beta2-agonists and increased asthma mortality....
AbstractThe development of inhaled agonists selective for β2-adrenoceptors and high potency corticos...
SummaryWe investigated the relationship between asthma mortality and long-acting beta2-agonists (LAB...
Long-acting -agonists are a pillar of therapy for many patients with asthma because they are the pre...
Background: Recent analyses have suggested an increased risk for serious asthma-related adverse even...
Several studies suggested an association between the regular use of β2-agonists and asthma deaths. ...
In a recent meta-analysis, Salpeter and colleagues documented a significant increase in life-threate...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
Background: It is unclear whether long-acting β-agonists with concomitant inhaled corticosteroids...
Large surveillance studies or phase IV clinical studies of long-acting β-agonists (LABA) compared wi...
Objective To determine the comparative effectiveness and safety of current maintenance strategies in...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
In patients with asthma, do long-acting β-agonists (LABAs) increase risk for asthma-related intubati...
International audienceBACKGROUND: Although several systematic reviews investigated the safety of lon...
The objective of this study was to describe risks of death and asthma outcomes with prescription of ...
Epidemiological evidence has suggested a link between beta2-agonists and increased asthma mortality....
AbstractThe development of inhaled agonists selective for β2-adrenoceptors and high potency corticos...
SummaryWe investigated the relationship between asthma mortality and long-acting beta2-agonists (LAB...
Add to ORKG